GOVERNANCE

Ensuring Transparency and Sustainable Growth

GOVERNANCE

Ensuring Transparency and Sustainable Growth

GOVERNANCE

Ensuring Transparency and Sustainable Growth

Young G. Shin

Professor, Chungnam National University, College of Pharmacy

Professor, Chungnam National University, College of Pharmacy

Dr. Young G. Shin is currently a Professor at the College of Pharmacy, Chungnam National University, South Korea. Dr. Shin began his career as an Investigator/Principal Scientist in the Drug Metabolism & Pharmacokinetics department at GlaxoSmithKline (Collegeville, PA, USA) before transitioning to the Drug Metabolism & Pharmacokinetics department at Genentech (South San Francisco, CA, USA). Dr. Shin’s main research areas include: 1). Development of fit-for-purpose bioanalytical/drug metabolism/ pharmacokinetics platforms for peptides, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), ASOs, siRNAs and small molecules for the lead optimization stage and beyond. 2) Development of in silico ADME lead optimization processes and human PK/metabolism prediction platforms using QSAR and PBPK modeling etc. Dr. Shin is also the founder of Korea-PBSS, a member organization of the PBSS-International (CA, USA). Dr. Shin received BSc, MSc, and Ph.D. from the College of Pharmacy at Seoul National University in Seoul, South Korea, and completed his post-doctoral training at the College of Pharmacy, University of Illinois, Chicago (IL, USA).

Dr. Young G. Shin is currently a Professor at the College of Pharmacy, Chungnam National University, South Korea. Dr. Shin began his career as an Investigator/Principal Scientist in the Drug Metabolism & Pharmacokinetics department at GlaxoSmithKline (Collegeville, PA, USA) before transitioning to the Drug Metabolism & Pharmacokinetics department at Genentech (South San Francisco, CA, USA). Dr. Shin’s main research areas include: 1). Development of fit-for-purpose bioanalytical/drug metabolism/ pharmacokinetics platforms for peptides, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), ASOs, siRNAs and small molecules for the lead optimization stage and beyond. 2) Development of in silico ADME lead optimization processes and human PK/metabolism prediction platforms using QSAR and PBPK modeling etc. Dr. Shin is also the founder of Korea-PBSS, a member organization of the PBSS-International (CA, USA). Dr. Shin received BSc, MSc, and Ph.D. from the College of Pharmacy at Seoul National University in Seoul, South Korea, and completed his post-doctoral training at the College of Pharmacy, University of Illinois, Chicago (IL, USA).

NEW RUN

NEW VENTURE™

5th Fl., N Center Bldg. A​​, 2066, Seobu-ro Jangan-gu, Suwon-si, Gyeonggi-do, Republic of Korea​ 16419

+82-31-278-7064

© IMNEWRUN INC. ALL RIGHTS RESERVED

NEW RUN

NEW VENTURE™

5th Fl., N Center Bldg. A​​, 2066, Seobu-ro Jangan-gu, Suwon-si, Gyeonggi-do, Republic of Korea​ 16419

+82-31-278-7064

© IMNEWRUN INC. ALL RIGHTS RESERVED

NEW RUN

NEW VENTURE™

5th Fl., N Center Bldg. A​​, 2066, Seobu-ro Jangan-gu, Suwon-si, Gyeonggi-do, Republic of Korea​ 16419

+82-31-278-7064

© IMNEWRUN INC. ALL RIGHTS RESERVED